Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPartners Grp E Regulatory News (PEY)

Share Price Information for Partners Grp E (PEY)

Share Price is delayed by 15 minutes
Get Live Data
8.48    -0.22 (-2.53%)
Bid:
8.48
Ask:
8.50
Spread: 0.02 (0.236%)
Market Cap: €574.17m
PEY Live PriceLast checked at - London Stock Exchange

Intraday Partners Grp E Share Chart

NAV increases by 1.0%

24 Feb 2017 07:00

RNS Number : 7329X
Princess Private Equity Holding Ltd
24 February 2017
 

News Release

Guernsey, 24 February 2017

 

NAV increases by 1.0%

 

· Princess Private Equity Holding Limited's ("Princess") net asset value ("NAV") increased by 1.0% to EUR 10.27 per share

· Currency movements (-0.2%) were slightly negative while overall portfolio developments (+1.2%) were positive

· Princess received distributions of EUR 1.3 million and invested EUR 12.6 million over the reporting period

 

Princess made an additional commitment of EUR 40 million to Partners Group Direct Equity 2016 program (previously announced following approval by the Board in November 2016) which held a closing during the month. This follows Princess' initial commitment of EUR 40 million to the program. As part of the equalization process to ensure equal treatment of investors in the program, Princess was subject to net capital calls of EUR 8.5 million (being the net of the equalization adjustments for each of Princess' commitments to the program). To-date Princess has committed a total of EUR 80 million to the Direct 2016 program, of which EUR 54.9 million remained undrawn as of month-end.

 

Distributions during January amounted to EUR 1.3 million of which EUR 1.1 million stemmed from the legacy fund portfolio.

 

Furthermore, Partners Group agreed to acquire a stake in Cerba Healthcare (Cerba), a leading operator of clinical pathology laboratories with a number one position in France and strong market positions in Belgium and Luxembourg. The majority of Cerba's revenues are generated via routine lab tests. The company also focuses on specialty lab testing for more complex medical diagnoses and testing services for clinical trials. Cerba's clients include private patients, physicians, labs, private and public hospitals, retirement and nursing homes, and pharmaceutical and biotech companies. The company employs almost 4,300 people, including 350 biologists, and generated revenues of approximately EUR 630 million in 2016. Princess will participate in the transaction which is expected to close in the coming months.

 

Further information is available in the monthly report which can be accessed via: http://www.princess-privateequity.net/financialreports.

 

Ends.

 

 

 

 

 

 

 

About Princess

Princess is an investment holding company founded in 1999 and domiciled in Guernsey. It invests, inter alia, in private equity and private debt investments. Princess is advised in its investment activities by Partners Group, a global private markets investment management firm with over EUR 54.2 billion in investment programs under management in private equity, private debt, private real estate and private infrastructure. Princess aims to provide shareholders with long-term capital growth and an attractive dividend yield. Princess is traded on the London Stock Exchange (ticker symbol: PEY). Further information: www.princess-privateequity.net.

 

Contacts

Princess Private Equity Holding Limited:

princess@partnersgroup.com

www.princess-privateequity.net

 

Registered Number: 35241

 

Investor relations contact

George Crowe

Phone: +44 (0)20 7575 2771

Email: george.crowe@partnersgroup.com

 

Media relations contact

Jenny Blinch

Phone: +41 41 784 65 26

Email: jenny.blinch@partnersgroup.com

www.partnersgroup.com

 

This document does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for any securities and neither is it intended to be an investment advertisement or sales instrument of Princess. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes must inform themselves about, and observe any such restrictions on the distribution of this document. In particular, this document and the information contained therein are not for distribution or publication, neither directly nor indirectly, in or into the United States of America, Canada, Australia or Japan.

 

This document may have been prepared using financial information contained in the books and records of the product described herein as of the reporting date. This information is believed to be accurate but has not been audited by any third party. This document may describe past performance, which may not be indicative of future results. No liability is accepted for any actions taken on the basis of the information provided in this document. Neither the contents of Princess' website nor the contents of any website accessible from hyperlinks on Princess' website (or any other website) is incorporated into, or forms part of, this announcement.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRUOOBRBNAUUAR
Date   Source Headline
9th Jun 20267:00 amRNSTransaction in Own Shares
27th May 20267:00 amRNSPGPE Ltd results presentation webcast details
18th May 20267:00 amRNSSave the date for Q1 2026 results announcement
7th May 20267:00 amRNSPGPE Ltd publishes March NAV
5th May 20267:00 amRNSDividend Declaration
1st May 20267:00 amRNSTransaction in Own Shares
30th Apr 20267:00 amRNSNotice of Annual General Meeting
14th Apr 20267:00 amRNSPGPE Ltd publishes February NAV
10th Apr 20267:00 amRNSTransaction in Own Shares
9th Apr 20267:00 amRNSTransaction in Own Shares
8th Apr 20267:00 amRNSBuyback update
7th Apr 20267:00 amRNSTransaction in Own Shares
31st Mar 20267:00 amRNSTransaction in Own Shares
30th Mar 20267:00 amRNSTransaction in Own Shares
23rd Mar 20267:00 amRNSAnnual results and webcast details
16th Mar 20267:00 amRNSSave the date for 2025 annual results announcement
16th Mar 20267:00 amRNSPGPE Ltd publishes January NAV
16th Mar 20267:00 amRNSSave the date for 2025 annual results announcement
16th Mar 20267:00 amRNSPGPE Ltd publishes January NAV
25th Feb 20267:00 amRNSTransaction in Own Shares
16th Feb 20267:00 amRNSPGPE Ltd publishes December NAV
12th Feb 20264:51 pmRNSHolding(s) in Company
12th Feb 20267:00 amRNSTransaction in Own Shares
9th Feb 20267:00 amRNSTransaction in Own Shares
5th Feb 20267:00 amRNSTransaction in Own Shares
30th Jan 20267:00 amRNSTransaction in Own Shares
29th Jan 20267:00 amRNSTransaction in Own Shares
28th Jan 20267:01 amRNSBuyback update
28th Jan 20267:00 amRNSTransaction in Own Shares
21st Jan 20267:00 amRNSTransaction in Own Shares
15th Jan 20267:00 amRNSTransaction in Own Shares
14th Jan 20267:00 amRNSFree Cash Flow as at 31 December 2025
8th Jan 20267:04 amRNSPGPE Ltd publishes November NAV
24th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20257:00 amRNSNAV increased by 0.5% in October
10th Dec 20257:00 amRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
28th Nov 20257:00 amRNSDirector/PDMR Shareholding
27th Nov 20257:05 amRNSSale of Convex Group
27th Nov 20257:00 amRNSEsentia lists on Mexican Stock Exchange
26th Nov 20257:00 amRNSTransaction in Own Shares
20th Nov 20257:00 amRNSResults presentation webcast details
20th Nov 20257:00 amRNSTransaction in Own Shares
13th Nov 20257:00 amRNSCredit facility renewed early
12th Nov 20257:00 amRNSTransaction in Own Shares
6th Nov 20257:00 amRNSDividend Declaration
4th Nov 20257:00 amRNSNAV increased by 2.1% in September
4th Nov 20257:00 amRNSSave the date for Q3 2025 results announcement
3rd Nov 20257:00 amRNSSale of Clario
30th Oct 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.